Trial Profile
A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Deudextromethorphan (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Avanir Pharmaceuticals; Otsuka Pharmaceutical Development & Commercialization
- 05 Apr 2024 Planned End Date changed from 1 Jul 2025 to 30 Jan 2025.
- 05 Apr 2024 Planned primary completion date changed from 1 Jul 2025 to 30 Jan 2025.
- 23 Mar 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Jul 2025.